2024 Event Site

Robert Scannevin, PhD

Dr. Scannevin has more than 23 years of leadership experience in drug discovery and development at both large pharma and early-stage biotech, and has seen multiple drugs from discovery through FDA approval. Before joining Verge, Dr. Scannevin was the Head of Research at Yumanity Therapeutics where he oversaw biology and chemistry research focused on new target discovery and therapeutic development for neurodegenerative diseases. While at Yumanity, he built a robust and efficient drugdiscovery function that delivered a deep discovery and clinical development pipeline. Dr. Scannevin provided scientific leadership that helped shepherd the company’s growth from early stages through multiple successful financing rounds, a collaboration with a major large pharmaceutical company, and to a successful public debut.

Prior to Yumanity, Dr. Scannevin was a Senior Director at Biogen, Inc. and has also led research teams atJohnson and Johnson (now Janssen) and Wyeth (now Pfizer). While at Biogen, Dr. Scannevin served on the preclinical development team for the Alzheimer’s disease antibody aducanumab and was heavily involved in the development and marketing approval of Tecfidera® (dimethyl fumarate), an oral therapeutic for multiple sclerosis, in which he served as the Global Research Lead for this first-in-class therapy.

Dr. Scannevin earned his PhD at SUNY Stony Brook in the laboratory of Dr. James S. Trimmer, and received his postdoctoral training at the Johns Hopkins University School of Medicine in the laboratory of Dr. Richard Huganir. He is a co-author on more than 60 peer-reviewed research articles and an inventor on over a dozen patent applications and issued patents.

Chief Scientific Officer, Verge Genomics


Join our email list to recieve exclusive offers

Opt In